MedPlus Health Services Limited (BOM:543427)
813.35
+9.00 (1.12%)
At close: Aug 14, 2025
MedPlus Health Services Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2021 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2021 |
61,899 | 61,361 | 56,249 | 45,576 | 37,793 | 30,693 | Upgrade | |
Revenue Growth (YoY) | 6.18% | 9.09% | 23.42% | 20.59% | 23.13% | 6.92% | Upgrade |
Cost of Revenue | 46,208 | 46,656 | 44,105 | 35,758 | 29,938 | 24,314 | Upgrade |
Gross Profit | 15,690 | 14,705 | 12,143 | 9,818 | 7,855 | 6,379 | Upgrade |
Selling, General & Admin | 7,646 | 7,441 | 6,508 | 5,565 | 4,010 | 3,405 | Upgrade |
Other Operating Expenses | 2,803 | 2,263 | 1,970 | 1,476 | 1,025 | 737.6 | Upgrade |
Operating Expenses | 13,004 | 12,202 | 10,721 | 8,857 | 6,228 | 5,025 | Upgrade |
Operating Income | 2,686 | 2,502 | 1,423 | 960.92 | 1,627 | 1,353 | Upgrade |
Interest Expense | -1,053 | -1,026 | -964.33 | -830.27 | -664.28 | -536.17 | Upgrade |
Interest & Investment Income | - | 259.91 | 209.36 | 277.88 | 137.32 | 77.94 | Upgrade |
Currency Exchange Gain (Loss) | - | 0.27 | 0.36 | 0.9 | -0.08 | -1.64 | Upgrade |
Other Non Operating Income (Expenses) | 549.23 | 25.65 | 25.21 | 23.65 | 42.3 | 19.81 | Upgrade |
EBT Excluding Unusual Items | 2,183 | 1,762 | 693.29 | 433.08 | 1,142 | 913.13 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.3 | Upgrade |
Gain (Loss) on Sale of Assets | - | -8.47 | -4.53 | -3.54 | -1.82 | -0.98 | Upgrade |
Asset Writedown | - | 66.67 | 45.22 | 42 | 38.18 | 23.79 | Upgrade |
Other Unusual Items | - | - | - | - | - | 12.78 | Upgrade |
Pretax Income | 2,183 | 1,833 | 734.43 | 471.63 | 1,179 | 950.98 | Upgrade |
Income Tax Expense | 400.36 | 330.56 | 78.66 | -29.42 | 232.27 | 319.87 | Upgrade |
Earnings From Continuing Operations | 1,782 | 1,502 | 655.77 | 501.05 | 947.16 | 631.11 | Upgrade |
Minority Interest in Earnings | 0.85 | 0.89 | -1.04 | -3.42 | 10.86 | 7.47 | Upgrade |
Net Income | 1,783 | 1,503 | 654.73 | 497.63 | 958.02 | 638.58 | Upgrade |
Net Income to Common | 1,783 | 1,503 | 654.73 | 497.63 | 958.02 | 638.58 | Upgrade |
Net Income Growth | 134.47% | 129.59% | 31.57% | -48.06% | 50.02% | 2829.27% | Upgrade |
Shares Outstanding (Basic) | 120 | 120 | 119 | 119 | 112 | 104 | Upgrade |
Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 112 | 108 | Upgrade |
Shares Change (YoY) | -0.28% | -0.00% | 0.31% | 6.38% | 3.82% | 0.17% | Upgrade |
EPS (Basic) | 14.91 | 12.57 | 5.48 | 4.17 | 8.55 | 6.13 | Upgrade |
EPS (Diluted) | 14.84 | 12.52 | 5.45 | 4.17 | 8.52 | 5.89 | Upgrade |
EPS Growth | 135.13% | 129.72% | 30.70% | -51.06% | 44.65% | 2815.86% | Upgrade |
Free Cash Flow | - | 4,810 | 593.38 | -785.97 | 521.68 | -513.66 | Upgrade |
Free Cash Flow Per Share | - | 40.07 | 4.94 | -6.57 | 4.64 | -4.74 | Upgrade |
Gross Margin | 25.35% | 23.96% | 21.59% | 21.54% | 20.78% | 20.78% | Upgrade |
Operating Margin | 4.34% | 4.08% | 2.53% | 2.11% | 4.30% | 4.41% | Upgrade |
Profit Margin | 2.88% | 2.45% | 1.16% | 1.09% | 2.54% | 2.08% | Upgrade |
Free Cash Flow Margin | - | 7.84% | 1.05% | -1.73% | 1.38% | -1.67% | Upgrade |
EBITDA | 3,485 | 3,239 | 2,085 | 1,412 | 1,867 | 1,520 | Upgrade |
EBITDA Margin | 5.63% | 5.28% | 3.71% | 3.10% | 4.94% | 4.95% | Upgrade |
D&A For EBITDA | 798.59 | 736.28 | 661.89 | 450.6 | 240.1 | 166.82 | Upgrade |
EBIT | 2,686 | 2,502 | 1,423 | 960.92 | 1,627 | 1,353 | Upgrade |
EBIT Margin | 4.34% | 4.08% | 2.53% | 2.11% | 4.30% | 4.41% | Upgrade |
Effective Tax Rate | 18.34% | 18.04% | 10.71% | - | 19.69% | 33.64% | Upgrade |
Revenue as Reported | 62,448 | 61,847 | 56,649 | 46,037 | 38,106 | 30,908 | Upgrade |
Advertising Expenses | - | 179.01 | 252.1 | 112.6 | 67.82 | 16.78 | Upgrade |
Updated Jan 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.